Dingdang Health Technology Group Ltd. conducted an on-market share repurchase on 20 October 2026, acquiring 848,000 ordinary shares for treasury at prices ranging between HK$0.85 and HK$0.885 per share. The transaction totalled HK$0.74 million, translating into a volume-weighted average cost of HK$0.8767 per share.
Following the buyback, the company’s outstanding share capital (excluding treasury shares) fell by 0.07% to 1,226.79 million shares, while treasury shares increased to 13.53 million. The total issued share count remained unchanged at 1,240.31 million.
The purchase was executed under the repurchase mandate approved on 23 June 2026, which authorises Dingdang Health to buy back up to 124.32 million shares. Including the latest transaction, the company has repurchased 16.38 million shares, representing 1.32% of the issued shares on the mandate date. No shares from the 20 October transaction have been cancelled; all remain in treasury.
Under Hong Kong Stock Exchange rules, the buyback triggers a 30-day moratorium—until 19 November 2026—during which the company may not issue, sell or transfer any treasury shares without prior Exchange approval.
Comments